Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 55 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 35 593.4
SNOMED-CT 68 197807001
UMLS 73 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to hydronephrosis and renal fibrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are Akt Signaling and TGF-Beta Pathway. The drugs Silodosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and prostate, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 hydronephrosis 31.2 AQP2 SLC12A1 TGFB1
2 renal fibrosis 30.9 AGTR1 BMP6 BMP7 TGFB1
3 colitis 29.5 CTNNB1 IL10 NOS2 PTGS2
4 familial adenomatous polyposis 29.3 CTNNB1 PTGS2 TP53
5 cervical cancer 27.5 CTNNB1 PTGS2 TP53 VEGFC
6 juvenile myasthenia gravis 10.7 IL10 TGFB1
7 ureteral disease 10.7 AQP2 BMP7 TGFB1
8 inflammatory bowel disease 25, autosomal recessive 10.7 IL10 TGFB1
9 familial vesicoureteral reflux 10.7 AGTR2 TGFB1
10 urinary tract obstruction 10.6 AQP2 PTGS2 TGFB1
11 leukoregulin 10.6 PTGS2 TGFB1
12 posterior urethral valves 10.6 AGTR1 AGTR2 TGFB1
13 end stage renal failure 10.5 AGTR1 EPO TGFB1
14 chagas disease 10.4 IL10 NOS2 TGFB1
15 leptospirosis 10.3 IL10 SLC12A1 SLC9A3
16 autoinflammation, lipodystrophy, and dermatosis syndrome 10.3 IL10 NOS2 PTGS2
17 fanconi-like syndrome 10.3 LRP2 PTGS2
18 adult hepatocellular carcinoma 10.3 CTNNB1 TP53
19 microvascular complications of diabetes 3 10.3 AGTR1 BMP6 TGFB1
20 protoplasmic astrocytoma 10.2 PTGS2 TP53
21 retroperitoneal fibrosis 10.2
22 congestive heart failure 10.1 AGTR1 AQP2 EPO
23 tuberculoid leprosy 10.1 BMP6 IL10 TGFB1
24 renal artery disease 10.1 AGTR1 EPO
25 anuria 10.1
26 aneurysm 10.1
27 endotheliitis 10.1
28 female reproductive endometrioid cancer 10.1 CTNNB1 TP53
29 vesicoureteral reflux 1 10.1
30 hypertension, essential 10.0 AGTR1 AGTR2 NOS2 SLC12A1
31 endometriosis 10.0
32 urinary system disease 10.0 AQP2 EPO LRP2 TGFB1
33 gastrointestinal system benign neoplasm 10.0 CTNNB1 PTGS2 TP53
34 intestinal benign neoplasm 10.0 CTNNB1 PTGS2 TP53
35 fibrosclerosis, multifocal 10.0
36 lipomatosis 10.0
37 pelvic lipomatosis 10.0
38 colorectal adenoma 10.0 CTNNB1 PTGS2 TP53
39 colorectal adenocarcinoma 10.0 CTNNB1 PTGS2 TP53
40 chronic kidney failure 9.9
41 pyelonephritis 9.9
42 cystitis 9.9
43 aortic aneurysm 9.9
44 kidney disease 9.9
45 hypoxia 9.9
46 uterine carcinosarcoma 9.9 CTNNB1 PTGS2 TP53
47 aortic aneurysm, familial abdominal, 1 9.9
48 prostatitis 9.9
49 vaginitis 9.9
50 ischemia 9.9

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

MGI Mouse Phenotypes related to Ureteral Obstruction:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 VEGFC TP53 CTNNB1 AGTR1 BMP7 AGTR2
2 homeostasis/metabolism MP:0005376 10.44 VEGFC TP53 AQP2 CTNNB1 AGTR1 AGTR2
3 growth/size/body region MP:0005378 10.43 TP53 AQP2 AGTR1 BMP6 BMP7 AGTR2
4 behavior/neurological MP:0005386 10.39 TP53 BMP7 AGTR2 AQP2 AGTR1 IL10
5 hematopoietic system MP:0005397 10.36 TP53 AQP2 AGTR1 BMP7 IL10 EPO
6 mortality/aging MP:0010768 10.35 TP53 VEGFC BMP7 AGTR2 AQP2 AGTR1
7 cellular MP:0005384 10.34 TP53 TGFB1 AGTR2 IL10 EPO HSPB1
8 immune system MP:0005387 10.34 TP53 VEGFC BMP7 AGTR1 IL10 EPO
9 digestive/alimentary MP:0005381 10.28 TP53 AGTR2 BMP7 IL10 CTNNB1 NOS2
10 endocrine/exocrine gland MP:0005379 10.27 TP53 BMP7 AGTR2 IL10 CTNNB1 LRP2
11 integument MP:0010771 10.25 TP53 AQP2 BMP7 AGTR2 EPO CTNNB1
12 embryo MP:0005380 10.18 TP53 TGFB1 BMP7 CTNNB1 EPO LRP2
13 adipose tissue MP:0005375 10.16 TP53 TGFB1 AGTR2 AGTR1 NOS2 SLC9A3
14 craniofacial MP:0005382 10.14 TP53 TGFB1 BMP7 CTNNB1 LRP2 IL10
15 nervous system MP:0003631 10.14 TP53 TGFB1 BMP7 AGTR2 AGTR1 IL10
16 renal/urinary system MP:0005367 10.13 TP53 AQP2 CTNNB1 AGTR1 BMP7 AGTR2
17 muscle MP:0005369 10.11 TP53 AGTR2 IL10 EPO CTNNB1 NOX4
18 liver/biliary system MP:0005370 10.04 TP53 TGFB1 CTNNB1 EPO IL10 NOS2
19 reproductive system MP:0005389 10.03 TP53 AQP2 BMP6 BMP7 CTNNB1 IL10
20 neoplasm MP:0002006 9.98 TP53 TGFB1 AGTR2 IL10 CTNNB1 NOS2
21 no phenotypic analysis MP:0003012 9.91 TP53 CTNNB1 HSPB1 LRP2 NOX4 IL10
22 respiratory system MP:0005388 9.85 TP53 BMP7 IL10 EPO CTNNB1 NOX4
23 skeleton MP:0005390 9.73 TP53 BMP6 BMP7 AGTR2 EPO CTNNB1
24 vision/eye MP:0005391 9.23 TP53 TGFB1 BMP7 CTNNB1 LRP2 IL10

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Silodosin Approved Phase 4 160970-54-7
2
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
3 Adrenergic Agents Phase 4,Phase 2
4 Adrenergic alpha-1 Receptor Antagonists Phase 4
5 Adrenergic alpha-Antagonists Phase 4
6 Adrenergic Antagonists Phase 4
7 Neurotransmitter Agents Phase 4,Phase 2
8 Tolterodine tartrate Phase 4 124937-52-6
9 Cholinergic Agents Phase 4
10 Muscarinic Antagonists Phase 4
11 Cholinergic Antagonists Phase 4
12 Fibrin Tissue Adhesive Phase 3
13 Coagulants Phase 3
14 Hemostatics Phase 3
15
Lidocaine Approved, Vet_approved Phase 2,Not Applicable 137-58-6 3676
16
Iodine Approved, Investigational Phase 2 7553-56-2 807
17
Floxuridine Approved Phase 2 50-91-9 5790
18
Fluorouracil Approved Phase 2 51-21-8 3385
19
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
20
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22 Mirabegron Approved Phase 2 223673-61-8 9865528
23
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25 Central Nervous System Depressants Phase 2,Not Applicable
26 Micronutrients Phase 2
27 Sodium Channel Blockers Phase 2,Not Applicable
28 Anesthetics Phase 2,Not Applicable
29 Trace Elements Phase 2
30 Anesthetics, Local Phase 2,Not Applicable
31 Diuretics, Potassium Sparing Phase 2,Not Applicable
32 Anti-Arrhythmia Agents Phase 2,Not Applicable
33 Peripheral Nervous System Agents Phase 2,Not Applicable
34 Vitamin B Complex Phase 2
35 Hypolipidemic Agents Phase 2
36 Vitamins Phase 2
37 Immunosuppressive Agents Phase 2
38 Antidotes Phase 2
39 Anti-Infective Agents Phase 2
40 Anti-Infective Agents, Local Phase 2
41 Protective Agents Phase 2
42 Liver Extracts Phase 2
43 Lipid Regulating Agents Phase 2
44 Antimetabolites Phase 2
45 Antimetabolites, Antineoplastic Phase 2
46 Calcium, Dietary Phase 2
47 Antiviral Agents Phase 2
48 Adrenergic Agonists Phase 2
49 Adrenergic beta-3 Receptor Agonists Phase 2
50 Adrenergic beta-Agonists Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Functional MR Urography Completed NCT00301470 Phase 4
3 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
4 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
5 Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation Completed NCT01631448 Phase 3
6 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
7 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
8 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
9 Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study Completed NCT01197248 Phase 2
10 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
11 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer Completed NCT00002842 Phase 2 floxuridine;fluorouracil;leucovorin calcium
12 Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
13 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain Not yet recruiting NCT02744430 Phase 2 Mirabegron
14 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
15 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431 Not Applicable
16 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent Completed NCT00166361 Not Applicable
17 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
18 Laparoscopic Pyeloplasty Registry and Database Completed NCT00169650
19 Evaluating Ureteral Length Using Computed Tomography (CT) Completed NCT01542593 Not Applicable
20 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine Completed NCT00930046 Not Applicable
21 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
22 Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery Completed NCT00840996 Not Applicable Lidocaine;placebo
23 Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
24 Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion Recruiting NCT03482089 Not Applicable
25 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082 Not Applicable
26 Local Treatment With RP for Newly-diagnosed mPCa Recruiting NCT02138721 Not Applicable
27 Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal Recruiting NCT02140970 Not Applicable Ibuprofen;Placebo
28 Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors Active, not recruiting NCT02276924 Not Applicable
29 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Enrolling by invitation NCT02160652
30 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770 Not Applicable
31 Ureteral Stent Versus Percutaneous Nephrostomy in Acutely Obstructed Infected Kidney Not yet recruiting NCT03498794 Not Applicable
32 CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212 Not Applicable
33 Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633 Not Applicable
34 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

41
Kidney, Liver, Prostate, Bone, Endothelial, Cervix, Monocytes

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 742)
# Title Authors Year
1
Ablation of C/EBP homologous protein attenuates renal fibrosis after ureteral obstruction by reducing autophagy and microtubule disruption. ( 29425932 )
2018
2
Effects of Qingshen Granules on the Oxidative Stress-NF/kB Signal Pathway in Unilateral Ureteral Obstruction Rats. ( 29576795 )
2018
3
pNaKtide ameliorates renal interstitial fibrosis through inhibition of sodium-potassium adenosine triphosphatase-mediated signaling pathways in unilateral ureteral obstruction mice. ( 29788096 )
2018
4
The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction. ( 29521269 )
2018
5
What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population? ( 29885870 )
2018
6
Cryptotanshinone Attenuates Oxidative Stress and Inflammation through the Regulation of Nrf-2 and NF-I_B in Mice with Unilateral Ureteral Obstruction. ( 29972887 )
2018
7
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
8
Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. ( 29518138 )
2018
9
Ureteral Obstruction Secondary to an Appendiceal Mucocele: A Case Report and Literature Review. ( 29845117 )
2018
10
Evaluation of renal metabolic response to partial ureteral obstruction with hyperpolarized<sup>13</sup>C MRI. ( 29130537 )
2018
11
Is hydrogen sulfide a potential novel therapy to prevent renal damage during ureteral obstruction? ( 29269061 )
2018
12
Outcome of ureteral stent placement for treatment of benign ureteral obstruction in dogs: 44 cases (2010-2013). ( 29504861 )
2018
13
Vimentin expression is required for the development of EMT-related renal fibrosis following Unilateral Ureteral Obstruction in mice. ( 29631355 )
2018
14
Ultrasonography in the diagnosis and management of cats with ureteral obstruction. ( 29172872 )
2018
15
No difference in renal injury and fibrosis between wild-type and NOD1/NOD2 double knockout mice with chronic kidney disease induced by ureteral obstruction. ( 29609537 )
2018
16
As in Real Estate, Location Is What Matters: A Case Report of Transplant Ureteral Obstruction Due to an Inguinal Hernia. ( 29372065 )
2018
17
Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-I^1-Smad-ILK pathway in unilateral ureteral obstruction rats. ( 29436600 )
2018
18
Thioredoxin-interacting protein deficiency ameliorates kidney inflammation and fibrosis in mice with unilateral ureteral obstruction. ( 29884908 )
2018
19
Encrusted Cystitis with Suspected Ureteral Obstruction Following Cystoscopic-Guided Laser Ablation of Ectopic Ureters in a Dog. ( 29372865 )
2018
20
Renal parenchyma impairment characterization in partial unilateral ureteral obstruction in mice with intravoxel incoherent motion-MRI. ( 29178439 )
2018
21
Comparison of T1 Mapping and T1rho Values with Conventional Diffusion-weighted Imaging to Assess Fibrosis in a Rat Model of Unilateral Ureteral Obstruction. ( 29705280 )
2018
22
Specific Inhibitor of Smad3 (SIS3) Attenuates Fibrosis, Apoptosis, and Inflammation in Unilateral Ureteral Obstruction Kidneys by Inhibition of Transforming Growth Factor I^ (TGF-I^)/Smad3 Signaling. ( 29555895 )
2018
23
Ureteric pyogenic granuloma: A peculiar case of ureteric obstruction. ( 29511640 )
2018
24
Bone marrowa89derived mesenchymal stem cella89conditioned medium attenuates tubulointerstitial fibrosis by inhibiting monocyte mobilization in an irreversible model of unilateral ureteral obstruction. ( 29620281 )
2018
25
Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. ( 29974220 )
2018
26
First Experience of Inserting a Metallic Mesh Stent (Uventa Stent) in Malignant Ureteral Obstruction in Iran. ( 29427286 )
2018
27
A Prospective Randomized Comparison of a Covered Metallic Ureteral Stent and a Double-J Stent for Malignant Ureteral Obstruction. ( 29962867 )
2018
28
Validation of a model of feline ureteral obstruction as a tool for teaching microsurgery to veterinary surgeons. ( 29380880 )
2018
29
Laparoscopic management of severe ureteral obstruction after vaginal hysterectomy and colposuspension. ( 29855661 )
2018
30
Effects of cholecalciferol cholesterol emulsion on renal fibrosis and aquaporin 2 and 4 in mice with unilateral ureteral obstruction. ( 29602131 )
2018
31
Does a Ureteral Obstruction Affect the Contralateral Kidney Morphology? A Stereological Analysis in a Rodent Model. ( 29421794 )
2018
32
The renal protect function of erythropoietin after releasing of bilateral ureteral obstruction in a rat model. ( 29959186 )
2018
33
Macrophages Regulate Unilateral Ureteral Obstruction-Induced Renal Lymphangiogenesis through C-C Motif Chemokine Receptor 2-Dependent Phosphatidylinositol 3-Kinase-AKT-Mechanistic Target ofA Rapamycin Signaling and Hypoxia-Inducible Factor-1I+/Vascular Endothelial Growth Factor-C Expression. ( 28627412 )
2017
34
Retrograde pyelography predicts retrograde ureteral stenting failure and reduces unnecessary stenting trials in patients with advanced non-urological malignant ureteral obstruction. ( 28931043 )
2017
35
Invasive Candida Infection with Ureteral Obstruction. ( 29279474 )
2017
36
Reactive oxygen species modulator 1 regulates oxidative stress and induces renal and pulmonary fibrosis in a unilateral ureteral obstruction rat model and in HKa892 cells. ( 28791399 )
2017
37
Deficiency of mPGES-1 exacerbates renal fibrosis and inflammation in mice with unilateral ureteral obstruction. ( 27784694 )
2017
38
Lee AS, Lee JE, Jung YJ, etA al. Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. Kidney Int. 2013;83:50-62. ( 28938942 )
2017
39
Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction. ( 28697727 )
2017
40
Mast Cells and MCPT4 Chymase Promote Renal Impairment after Partial Ureteral Obstruction. ( 28523000 )
2017
41
Demethylzeylasteral ameliorates inflammation in a rat model of unilateral ureteral obstruction through inhibiting activation of the NFa89I_B pathway. ( 28534978 )
2017
42
Thymoquinone ameliorates renal damage in unilateral ureteral obstruction in rats. ( 28521173 )
2017
43
Fluoride potentiates tubulointerstitial nephropathy caused by unilateral ureteral obstruction. ( 29024711 )
2017
44
Ethanol extract of gardenia fruit alleviates renal interstitial fibrosis induced by unilateral ureteral obstruction in rats. ( 28810600 )
2017
45
Human Umbilical Cord-Derived Mesenchymal Stem Cells Conditioned Medium Attenuate Interstitial Fibrosis and Stimulate the Repair of Tubular Epithelial Cells in an Irreversible Model of Unilateral Ureteral Obstruction. ( 28667820 )
2017
46
Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction. ( 27763657 )
2017
47
Inguinal Bladder Hernia With Acute Ureteral Obstruction 14 Years After Kidney Transplantation: A Case Report. ( 28838448 )
2017
48
Postrenal acute kidney injury in a patient with unilateral ureteral obstruction caused by urolithiasis: A case report. ( 29069033 )
2017
49
Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction. ( 29194771 )
2017
50
Kidney Injury due to Ureteral Obstruction Caused by Compression from Infected Simple Hepatic Cyst. ( 28626377 )
2017

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 BMP6 BMP7 HSPB1 IL10 TGFB1 TP53
2
Show member pathways
13.3 AGTR1 AGTR2 BMP6 BMP7 EPO HSPB1
3
Show member pathways
13.2 BMP6 BMP7 CTNNB1 IL10 NOX4 TGFB1
4
Show member pathways
12.93 BMP6 BMP7 CTNNB1 NOS2 PTGS2 VEGFC
5
Show member pathways
12.92 AGTR1 AGTR2 BMP6 BMP7 PTGS2 TGFB1
6
Show member pathways
12.45 AGTR1 CTNNB1 IL10 NOS2 TP53
7
Show member pathways
12.39 BMP7 CTNNB1 NOX4 TGFB1
8
Show member pathways
12.3 CTNNB1 HSPB1 NOS2 PTGS2
9
Show member pathways
12.15 IL10 NOS2 PTGS2 TGFB1
10 12.13 BMP6 BMP7 CTNNB1 TGFB1
11 12.07 CTNNB1 NOS2 PTGS2 TGFB1 TP53
12 12.02 BMP6 BMP7 CTNNB1 TGFB1
13
Show member pathways
11.96 BMP6 BMP7 IL10 TGFB1 VEGFC
14 11.95 AGTR1 CTNNB1 EPO NOS2 PTGS2 TGFB1
15 11.88 NOS2 NOX4 PTGS2 TGFB1 TP53
16 11.81 AGTR1 NOX4 TGFB1 VEGFC
17 11.78 NOS2 PTGS2 TP53
18 11.78 IL10 NOS2 PTGS2 TGFB1 TP53
19
Show member pathways
11.77 CTNNB1 HSPB1 VEGFC
20 11.76 HSPB1 IL10 NOS2 TGFB1
21 11.75 PTGS2 TGFB1 VEGFC
22 11.72 BMP6 BMP7 TGFB1
23
Show member pathways
11.68 AGTR1 AGTR2 TGFB1
24 11.59 BMP6 BMP7 TGFB1
25 11.52 BMP6 BMP7 CTNNB1 HSPB1 TGFB1 TP53
26 11.47 EPO TP53 VEGFC
27 11.44 NOS2 PTGS2 TGFB1 TP53
28 11.13 EPO NOS2 PTGS2 TP53
29 11 HSPB1 NOS2 PTGS2 TP53

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 AQP2 LRP2 NOX4 SLC12A1 SLC9A3

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.98 AGTR2 BMP7 CTNNB1 EPO IL10 TGFB1
2 cytokine-mediated signaling pathway GO:0019221 9.97 IL10 NOS2 PTGS2 TGFB1 TP53
3 response to drug GO:0042493 9.96 CTNNB1 IL10 PTGS2 TGFB1 VEGFC
4 response to lipopolysaccharide GO:0032496 9.95 EPO IL10 NOS2 PTGS2
5 regulation of signaling receptor activity GO:0010469 9.95 BMP6 BMP7 EPO IL10 TGFB1 VEGFC
6 regulation of cell proliferation GO:0042127 9.91 AGTR1 CTNNB1 NOS2 PTGS2 TGFB1
7 response to organic substance GO:0010033 9.88 IL10 PTGS2 TGFB1
8 positive regulation of apoptotic process GO:0043065 9.88 BMP7 CTNNB1 NOX4 PTGS2 TGFB1 TP53
9 BMP signaling pathway GO:0030509 9.87 BMP6 BMP7 TGFB1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 TGFB1 TP53 VEGFC
11 positive regulation of neuron differentiation GO:0045666 9.86 BMP6 BMP7 EPO
12 cellular response to mechanical stimulus GO:0071260 9.85 BMP6 PTGS2 TGFB1
13 positive regulation of endothelial cell proliferation GO:0001938 9.84 BMP6 IL10 VEGFC
14 response to glucocorticoid GO:0051384 9.83 BMP6 IL10 PTGS2
15 positive regulation of epithelial cell proliferation GO:0050679 9.83 BMP6 TGFB1 VEGFC
16 kidney development GO:0001822 9.83 AGTR1 BMP6 BMP7 CTNNB1
17 SMAD protein signal transduction GO:0060395 9.82 BMP6 BMP7 TGFB1
18 cell development GO:0048468 9.82 BMP6 BMP7 TGFB1
19 regulation of MAPK cascade GO:0043408 9.81 BMP6 BMP7 TGFB1
20 positive regulation of osteoblast differentiation GO:0045669 9.81 BMP6 BMP7 CTNNB1
21 response to estradiol GO:0032355 9.8 BMP7 CTNNB1 PTGS2 TGFB1
22 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.79 BMP6 BMP7 TGFB1
23 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 HSPB1 TGFB1 VEGFC
24 positive regulation of epithelial to mesenchymal transition GO:0010718 9.78 BMP7 CTNNB1 TGFB1
25 negative regulation of cell cycle GO:0045786 9.77 BMP7 PTGS2 TGFB1
26 aging GO:0007568 9.77 EPO IL10 NOX4 PTGS2 TGFB1
27 positive regulation of protein secretion GO:0050714 9.76 BMP6 TGFB1 VEGFC
28 epithelial to mesenchymal transition GO:0001837 9.75 BMP7 CTNNB1 TGFB1
29 regulation of apoptotic process GO:0042981 9.73 AGTR2 BMP6 BMP7 CTNNB1 TGFB1 TP53
30 positive regulation of bone mineralization GO:0030501 9.72 BMP6 BMP7 TGFB1
31 response to hypoxia GO:0001666 9.72 EPO NOS2 NOX4 TGFB1 VEGFC
32 positive regulation of reactive oxygen species metabolic process GO:2000379 9.71 AGTR1 NOX4 TP53
33 regulation of blood vessel diameter GO:0097746 9.7 AGTR1 AGTR2
34 positive regulation of cell proliferation GO:0008284 9.7 AGTR2 BMP6 CTNNB1 EPO PTGS2 TGFB1
35 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 BMP7 IL10
36 positive regulation of SMAD protein signal transduction GO:0060391 9.69 BMP6 TGFB1
37 morphogenesis of embryonic epithelium GO:0016331 9.68 CTNNB1 VEGFC
38 positive regulation of histone deacetylation GO:0031065 9.68 TGFB1 TP53
39 salivary gland morphogenesis GO:0007435 9.67 BMP7 TGFB1
40 angiotensin-activated signaling pathway GO:0038166 9.67 AGTR1 AGTR2
41 regulation of protein import into nucleus GO:0042306 9.66 AGTR2 TGFB1
42 response to vitamin D GO:0033280 9.63 BMP7 PTGS2 TGFB1
43 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.62 EPO PTGS2
44 renin-angiotensin regulation of aldosterone production GO:0002018 9.59 AGTR1 AGTR2
45 inflammatory response GO:0006954 9.5 AGTR2 BMP6 IL10 NOS2 NOX4 PTGS2
46 negative regulation of cell proliferation GO:0008285 9.23 BMP7 CTNNB1 IL10 NOX4 PTGS2 TGFB1
47 negative regulation of apoptotic process GO:0043066 10.1 EPO HSPB1 IL10 PTGS2 TP53
48 cell proliferation GO:0008283 10.03 CTNNB1 EPO LRP2 TGFB1 TP53

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 AGTR1 BMP6 CTNNB1 TGFB1 TP53
2 cytokine activity GO:0005125 9.55 BMP6 BMP7 EPO IL10 TGFB1
3 transforming growth factor beta receptor binding GO:0005160 9.5 BMP6 BMP7 TGFB1
4 growth factor activity GO:0008083 9.35 BMP6 BMP7 IL10 TGFB1 VEGFC
5 angiotensin type II receptor activity GO:0004945 9.26 AGTR1 AGTR2
6 BMP receptor binding GO:0070700 8.8 BMP6 BMP7 TGFB1
7 protein binding GO:0005515 10.3 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO

Sources for Ureteral Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....